Clinically significant anxiety as a risk factor for Alzheimer's disease: Results from a 10‐year follow‐up community study

Abstract

Abstract Objective There is growing evidence for an association between anxiety and an increased risk of dementia, but it is not clear whether anxiety is a risk factor or a prodromic symptom. In this study, we investigated if clinically significant anxiety increases the risk of developing Alzheimer's disease (AD) up to 10 years later. Methods We used data from the longitudinal Zaragoza Dementia and Depression (ZARADEMP) Project. Excluding subjects with dementia at baseline left us with 3044 individuals aged >65 years. The Geriatric Mental State‐Automated Geriatric Examination for Computer Assisted Taxonomy (GMS‐AGECAT) package was used to identify cases and subcases of anxiety. AD was diagnosed by a panel of research psychiatrists according to the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM‐IV) criteria. Multivariate survival analysis with a competing risk regression model was performed. Results We observed a significant association between clinically significant anxiety at baseline and AD risk within a 10‐year follow‐up (SHR 2.82 [95% CI 1.21–6.58]), after controlling for confounders including depression. In contrast, isolated symptoms of anxiety were not significantly associated with an increased incidence of AD. Conclusion Our results support the hypothesis that clinically significant anxiety is an independent risk factor for AD and not just a prodromic symptom. Future studies should clarify if treating anxiety reduces the incidence of AD.

Keywords

• Alzheimer's disease
• competing risk
• risk factor
• ZARADEMP